trial

Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)

NCTId NCT00212771
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 440 (actual)
Sponsored by Organon and Co
Primary completion 2006-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
440 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2004-09
Primary completion
2006-09
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
AsenapineOlanzapine

Sponsors

Organon and CoLead Sponsor

Sites

0 total

Linked catalysts

1
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizo — primary completion2006-09

Facts & assertions

4 sourced
Enrollment
440
Phase
PHASE3
Primary Completion Date
2006-09
Status
COMPLETED
relationships
The graph out of here
drug
Asenapine
drug
Olanzapine
drug
lead_sponsor
Organon and Co
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication